1
|
Kim TE, Yoon YR. Clinical pharmacology and therapeutics in South Korea: 30 years with the Korean Society of Clinical Pharmacology and Therapeutics. Transl Clin Pharmacol 2024; 32:115-126. [PMID: 39386268 PMCID: PMC11458341 DOI: 10.12793/tcp.2024.32.e12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2024] [Revised: 09/12/2024] [Accepted: 09/13/2024] [Indexed: 10/12/2024] Open
Affiliation(s)
- Tae-Eun Kim
- Department of Clinical Pharmacology, Konkuk University Medical Center, Seoul 05029, Korea
- Korean Society of Clinical Pharmacology and Therapeutics, Seoul 04143, Korea
| | - Young-Ran Yoon
- Korean Society of Clinical Pharmacology and Therapeutics, Seoul 04143, Korea
- Department of Molecular Medicine, School of Medicine, Kyungpook National University and Department of Clinical Pharmacology, Kyungpook National University Hospital, Daegu 41944, Korea
| |
Collapse
|
2
|
Lin Y, Long Y, Wang Y, Wang L, Wang M, Xia X, Chen X, Huang Y, Du P, Wu J, Jia Y, Shen J. Age-related pharmacokinetics differences were observed between young and elderly populations of a novel PDE5 inhibitor, youkenafil, and its metabolite M459. Eur J Pharm Sci 2024; 196:106755. [PMID: 38556064 DOI: 10.1016/j.ejps.2024.106755] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2023] [Revised: 03/08/2024] [Accepted: 03/28/2024] [Indexed: 04/02/2024]
Abstract
PURPOSE Youkenafil is a novel oral selective PDE5 inhibitor for treating Erectile Dysfunction. This investigation assessed pharmacokinetics (PK), safety, and tolerability of youkenafil and its main metabolite (M459) after taking 100 mg youkenafil hydrochloride tablets in elderly and young subjects. METHODS This Phase I, single-center, open-label, parallel-group, single-dose study was conducted on 24 individuals (12 elders and 12 youngsters). Each subject received a single oral 100 mg youkenafil hydrochloride tablets. Blood samples were collected before medication and up to 48 h after medication for PK analysis. Safety and tolerability were also assessed, including treatment-emergent adverse events (TEAEs), laboratory tests, 12-lead ECG, vital sign inspections, color vision examinations, and physical examinations. RESULTS Plasma concentrations of youkenafil and M459 were quantified. PK parameters were determined by non-compartmental analysis. Median Tmax of elderly and young groups were both 0.733 h. However, Cmax, AUC0-t, and AUC0-∞ of youkenafil were separately 16.8 %, 37.2 %, and 37.5 % higher in elders and t1/2 of youkenafil was 2.1 h longer in elders. More great differences were observed for M459. T1/2 values were 4.05 h longer in elders, with Cmax, AUC0-t and AUC0-∞ 73.7 %, 81.1 %, and 81.4 % higher in elders. Two (8.3 %) elderly subjects reported TEAEs (all grade Ⅰ in severity) and both recovered without any treatment. No serious adverse reactions (SAEs) or serious unexpected suspected adverse reactions (SUSARs) occurred in this study. CONCLUSIONS This was the first PK research of youkenafil and M459 in elderly men. PK parameters differences between youkenafil and M459 were comparable between elderly and young groups. Moreover, safety and tolerability of youkenafil were favorable in both groups.
Collapse
Affiliation(s)
- Yuhong Lin
- Anhui Provincial Center of Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR China; School of Pharmacy, Wannan Medical College, Wuhu, Anhui, PR China
| | - Yao Long
- Anhui Provincial Center of Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR China; School of Pharmacy, Wannan Medical College, Wuhu, Anhui, PR China
| | - Yaqin Wang
- Anhui Provincial Center of Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR China
| | - Lin Wang
- Anhui Provincial Center of Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR China
| | - Minhui Wang
- Anhui Provincial Center of Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR China
| | - Xiaocui Xia
- Anhui Provincial Center of Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR China
| | - Xinyan Chen
- School of Pharmacy, Wannan Medical College, Wuhu, Anhui, PR China
| | - Yunzhe Huang
- School of Pharmacy, Wannan Medical College, Wuhu, Anhui, PR China
| | - Pengfei Du
- School of Pharmacy, Wannan Medical College, Wuhu, Anhui, PR China
| | - Jianbang Wu
- School of Pharmacy, Wannan Medical College, Wuhu, Anhui, PR China
| | - Yuanwei Jia
- Anhui Provincial Center of Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR China; School of Pharmacy, Wannan Medical College, Wuhu, Anhui, PR China.
| | - Jie Shen
- Anhui Provincial Center of Drug Clinical Evaluation, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, PR China; School of Pharmacy, Wannan Medical College, Wuhu, Anhui, PR China.
| |
Collapse
|
3
|
Cho YS, Noh YH, Lim HS, Cho SH, Ghim JL, Choe S, Kim SB, Park JS, Lee SK, Yang WS, Chang JW, Bahng MY, Bae KS. Effects of Renal Impairment on the Pharmacokinetics and Safety of Udenafil. J Clin Pharmacol 2018. [DOI: 10.1002/jcph.1095] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Affiliation(s)
- Yong-Soon Cho
- Department of Clinical Pharmacology and Therapeutics; University of Ulsan; Seoul Republic of Korea
| | - Yook-Hwan Noh
- Hallym Institute for Clinical Medicine; Hallym University Medical Center; Anyang Gyeonggi-do Republic of Korea
| | - Hyeong-Seok Lim
- Department of Clinical Pharmacology and Therapeutics; University of Ulsan; Seoul Republic of Korea
| | - Sang-Heon Cho
- Department of Clinical Pharmacology and Therapeutics; Inha University; Incheon Republic of Korea
| | - Jong-Lyul Ghim
- Department of Clinical Pharmacology; Korea University Anam Hospital; Seoul Republic of Korea
| | - Sangmin Choe
- Clinical Trials Center; Pusan National University Hospital; Busan Republic of Korea
| | - Soon-Bae Kim
- Department of Internal Medicine; University of Ulsan; Seoul South Korea
| | - Jung-Sik Park
- Department of Internal Medicine; University of Ulsan; Seoul South Korea
| | - Sang-Koo Lee
- Department of Internal Medicine; University of Ulsan; Seoul South Korea
| | - Won-Seok Yang
- Department of Internal Medicine; University of Ulsan; Seoul South Korea
| | - Jai-Won Chang
- Department of Internal Medicine; University of Ulsan; Seoul South Korea
| | - Mi-Young Bahng
- Department of Product Development; Dong-A ST Seoul Republic of Korea
| | - Kyun-Seop Bae
- Department of Clinical Pharmacology and Therapeutics; University of Ulsan; Seoul Republic of Korea
| |
Collapse
|